School of Public Health, University of California, Berkeley, Berkeley, CA.
Division of Research, Kaiser Permanente Northern California, Oakland, CA.
Perm J. 2021 Oct 25;26(1):11-20. doi: 10.7812/TPP/21.024.
Effective, equity-promoting interventions implemented by health care systems are needed to address health care disparities and population-level health disparities. We evaluated the impact of a clinical decision support tool to improve evidence-based thiazide diuretic prescribing among Black patients to address racial disparities in hypertension control.
We employed an interrupted time series design and qualitative interviews to evaluate the implementation of the tool. Our primary outcome measure was the monthly rate of thiazide use among eligible patients before and after implementation of the tool (January 2013-December 2016). We modeled month-to-month changes in thiazide use for Black and White patients, overall, and by sex and medical center racial composition. We conducted key informant interviews to identify modifiable facilitators and barriers to implementation of the tool across medical centers.
Of the 318,720 patients, 15.5% were Black. We observed no change in thiazide use or blood pressure control following the implementation of the tool in either racial subgroup. There was a slight but statistically significant reduction (2.32 percentage points, p < 0.01) in thiazide use among Black patients following the removal the tool that was not observed among White patients. Factors affecting the tool's implementation included physician and pharmacist resistance to thiazide use and a lack of ongoing promotion of the tool.
The clinical decision support tool was insufficient to change prescribing practices and improve blood pressure control among Black patients.
Future interventions should consider physician attitudes about thiazide prescribing and the importance of multilevel approaches to address hypertension disparities.
需要医疗保健系统实施有效、促进公平的干预措施,以解决医疗保健差异和人群健康差异问题。我们评估了一种临床决策支持工具的效果,该工具旨在改善针对黑人患者的噻嗪类利尿剂处方,以解决高血压控制方面的种族差异。
我们采用了中断时间序列设计和定性访谈来评估工具的实施情况。我们的主要结果测量是在工具实施前后(2013 年 1 月至 2016 年 12 月)符合条件的患者每月噻嗪类药物使用的比例。我们对黑人和白人患者、总体以及按性别和医疗中心种族构成的噻嗪类药物使用的月变化进行建模。我们进行了关键知情人访谈,以确定跨医疗中心实施工具的可改变的促进因素和障碍。
在 318720 名患者中,15.5%为黑人。我们观察到在工具实施后,无论在哪个种族亚组中,噻嗪类药物的使用或血压控制都没有变化。在去除该工具后,黑人患者的噻嗪类药物使用略有但统计学上显著减少(2.32 个百分点,p < 0.01),而白人患者则没有观察到这种情况。影响工具实施的因素包括医生和药剂师对噻嗪类药物使用的抵制以及缺乏对该工具的持续推广。
临床决策支持工具不足以改变处方实践并改善黑人患者的血压控制。
未来的干预措施应考虑医生对噻嗪类药物处方的态度以及采用多层次方法解决高血压差异的重要性。